Ovarian Cancer Clinical Trial
— ECHOOfficial title:
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: a Phase II Clinical Study
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in tampon-collected vaginal fluid and 2) ovarian cancer (OC) in plasma and tampon-collected vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.
Status | Recruiting |
Enrollment | 2640 |
Est. completion date | December 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for Cohort 1: Women will be =45 years of age and meet at least one of the following criteria: - Abnormal uterine bleeding - Postmenopausal bleeding Exclusion Criteria for Cohort 1: - Prior hysterectomy - Current known pregnancy diagnosis - Any prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia - Current biopsy-proven endometrial cancer or endometrial hyperplasia - - - Current biopsy-proven benign endometrial polyp - Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium Inclusion Criteria for Cohort 2: Women will be =18 years of age and meet at least one of the following criteria: - Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection - Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection, etc) Exclusion Criteria for Cohort 2: - Undergoing surgical procedure for recurrent or metastatic EC - Receipt of preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis - Prior hysterectomy - Current known pregnancy diagnosis - Prior or current biopsy-proven cervical cancer - Presence of concomitant biopsy-proven cervical dysplasia - Any prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Prior intervention or surgery with intent to completely remove the target pathology Inclusion Criteria for Cohort 3: Women will be =18 years of age, have a cervix and meet at least one of the following criteria: - History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy - Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated - Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible) Exclusion Criteria for Cohort 3: - History of pelvic or vaginal radiotherapy - Prior total hysterectomy (cervix removed) for any indication - Current known pregnancy diagnosis - Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass - Prior intervention or surgery with intent to completely remove the target pathology Inclusion Criteria for Cohort 4: Women will be =45 years of age and should meet at least one of the following criteria: - Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps. - Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed. Exclusion Criteria for Cohort 4: - Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis - Any surgery within the past 3 months - Prior hysterectomy - Current known pregnancy diagnosis - Prior or current biopsy-proven gynecologic cancer - Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia - Prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis - Prior intervention or surgery with intent to completely remove the target pathology Inclusion Criteria for Cohort 5: Women will be =45 years of age and should meet the following criteria: - Presenting for well-woman exam, ± Pap test - No change in medical conditions, new diagnoses, or new medications within the past 6 months; Exclusion Criteria for Cohort 5: - Pap test or cervical biopsy within the past 1 month - Endometrial biopsy or office hysteroscopy within the past 1 month - Any surgery within the past 3 months - Prior hysterectomy - Current known pregnancy diagnosis - Prior or current biopsy-proven gynecologic cancer - Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia - Prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Criteria met for inclusion in any of the other study cohorts Inclusion Criteria for Cohort 6: Women =50 years of age and: - Postmenopausal status - At least 1 intact ovary - Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer) - Planned surgery for the adnexal mass - For tampon collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion) Exclusion criteria - Isolated Adnexal Mass cohort: (Cohort 6) - Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) - Chemotherapy for cancer treatment within the past 5 years prior to collection - Clinically-suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection - Surgical candidates for recurrent ovarian cancer - History of pelvic or vaginal radiation therapy - Known current synchronous endometrial cancer or hyperplasia - Known current cervical, vaginal, or vulvar dysplasia Inclusion criteria - OC Cohort: (Cohort 7) Women will be =18 years of age and meet the following criteria: - Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any/all of the following: imaging showing adnexal and/or abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology - Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy - At least one intact ovary - For tampon collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion) Exclusion criteria - OC Cohort (Cohort 7): - Patients with recurrent OC - Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years - Chemotherapy for cancer treatment within the past 5 years prior to collection - History of pelvic or vaginal radiation therapy - Known current synchronous endometrial cancer or hyperplasia - Known current cervical, vaginal, or vulvar dysplasia |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Providea Health Partners, LLC | Evergreen Park | Illinois |
United States | Altru Health System | Grand Forks | North Dakota |
United States | The Woman's Health Pavilion | Howard Beach | New York |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Mayo Clinic | Jacksonville | Florida |
United States | Medical Colleagues of Texas, LLP | Katy | Texas |
United States | Genoma Research, Inc. | Miami | Florida |
United States | My GYN Care | Miami | Florida |
United States | Signature Women's Healthcare, LLC | Pembroke Pines | Florida |
United States | Mayo Clinic | Phoenix | Arizona |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Valley OB-GYN Clinic | Saginaw | Michigan |
United States | Sarasota Memorial Health Care System | Sarasota | Florida |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Develop predictive models from a panel of EC-specific MDMs and validate their performance in identifying underlying EC and AEH within tampon-collected vaginal fluid in a larger, more diverse cohort. | Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based endometrial cancer detection test performed on vaginal fluid collected via intravaginal tampon. The phase II aspect of this biomarker development study will narrow the number of endometrial cancer MDMs within the biomarker panel in order to optimize the next phase of test development. | 18 months | |
Primary | Develop predictive models from a panel of OC-specific MDMs and validate their performance in identifying underlying OC within tampon-collected vaginal fluid and plasma in a larger, more diverse cohort. | Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based ovarian cancer detection test performed on vaginal fluid collected via intravaginal tampon. The phase II aspect of this biomarker development study will narrow the number of ovarian cancer MDMs within the biomarker panel in order to optimize the next phase of test development. | 18 months | |
Secondary | Using 95% specificity cutoffs of the final tampon-based MDM EC panel, determine the false positive rate among women undergoing surgical removal of common benign gynecologic pathology | As part of this biomarker test development, understanding whether common non-cancerous uterine or gynecologic conditions may also lead to the finding of currently apparent endometrial cancer-specific MDMs in vaginal fluid is critical in determining specificity, positive predictive value, and negative predictive value of the test. | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |